This grant application responds to Program Announcement Number PA-11-110 (Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD and Other Dual Doctoral Degree Fellows) by proposing to develop novel evolutionary platforms and apply computational modeling strategies to engineer soluble HIV gp140 trimers and epitope-scaffold mimetics with improved stability and accessibility of key functionally conserved quaternary broadly neutralizing antibody (bNAb) epitopes. These epitope-focused antigens are expected to elicit broadly neutralizing responses more strongly than native viral trimers, which evade immune recognition by providing limited access to functionally critical epitopes. Epitope-focused antigens may be used as vaccine candidates, baits for isolation of new bNAbs, and epitope probes to characterize serum antibody responses. To engineer epitope-focused trimers, a platform for yeast display of trimeric gp140 envelope will be developed and used to generate both randomly and rationally mutated libraries of trimers. These libraries will be evolved for enhanced binding to quaternary epitope-specific bNAbs to isolate epitope-focused candidate trimers. To engineer epitope-focused mimetics, a computational protein peeling strategy developed by collaborators will be applied to generate rewired epitope-scaffolds of quaternary epitopes. We will produce and test the designed epitope-scaffolds for expression, stability, aggregation propensity, and binding to conformational monoclonal bNAbs. The top-performing candidates will then be carried into immunogenicity studies in mice to determine whether elicited antibody responses target the intended epitopes and recognize natively folded trimers. By the end of the proposed funding period, we expect to have generated a widely applicable novel platform for directed evolution of multimeric proteins, an improved computational protein peeling method for generation of rewired epitope-scaffold mimetics informed by our results, and multiple quaternary epitope-focused vaccine candidates. These advances will serve the global community by offering both strategies towards and candidates for the development of HIV vaccines with improved elicitation of protective broadly neutralizing antibody responses.

Public Health Relevance

This project aims to develop novel HIV vaccine candidates by focusing the immune response against functionally conserved, critical regions of the viral surface envelope protein, the targets of protective broadly neutralizing antibodies. Evolutionary platforms allowing the sampling of billions of candidate immunogens at once and computational modeling approaches will be developed and applied to engineer HIV vaccine candidates with enhanced presentation of such vulnerable regions shared across diverse viral strains. These advances will serve the global community by offering both strategies towards and candidates for the development of a protective HIV vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
5F30AI122970-03
Application #
9458696
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Warren, Jon T
Project Start
2016-04-01
Project End
2019-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Type
Graduate Schools
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
Hua, Casey K; Gacerez, Albert T; Sentman, Charles L et al. (2017) Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6. Protein Eng Des Sel 30:713-721
Hua, Casey K; Ackerman, Margaret E (2017) Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. Front Immunol 8:1655
Hua, Casey K; Gacerez, Albert T; Sentman, Charles L et al. (2017) Computationally-driven identification of antibody epitopes. Elife 6:
Hua, Casey K; Ackerman, Margaret E (2016) Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev 103:157-73